U-76,252 is the prodrug of U-76,253. MICs of U-76,253 were 0.015 to 0.06 ,Ig/ml for -90% of the strains of Streptococcus spp., Haemophilus influenzae, and Proteus mirabilis; 0.25 to 1 ,ug/ml for Branhamella catarrhalis, Escherichia coli, Klebsiella spp., and Citrobacter diversus; 1 to 8 ,ug/ml for Staphylococcus spp.; and 2 to >16 ,ug/ml for other members of the family Enterobacteriaceae and Aeromonas hydrophila; for 72% of the latter group, MICs were <4 ,ug/mI. MICs for Pseudomonas aeruginosa and Enterococcusfaecalis were > 16 ,ug/ ml. is the oral prodrug of U-76,253 (R-3746), a cephalosporin that has a broad spectrum of antibacterial activity, is resistant to hydrolysis by many p-lactamases, and is bactericidal in activity (4). In this study, we compared the in vitro activity of U-76,253 with the activities of other oral antimicrobial agents against a variety of aerobic and facultatively anaerobic bacterial species.
is the oral prodrug of U-76,253 (R-3746), a cephalosporin that has a broad spectrum of antibacterial activity, is resistant to hydrolysis by many p-lactamases, and is bactericidal in activity (4) . In this study, we compared the in vitro activity of U-76,253 with the activities of other oral antimicrobial agents against a variety of aerobic and facultatively anaerobic bacterial species.
The organisms studied included 664 bacterial strains isolated from patients at The Ohio State University Hospitals.
Strains of Haemophilus influenzae (47 P-lactamase negative and 50 P-lactamase positive), Branhamella catarrhalis (six ,B-lactamase negative and 14 ,-lactamase positive), and Streptococcus pyogenes were isolated primarily from respiratory secretions; strains of Staphylococcus saprophyticus were isolated primarily from the urinary tract. Of other strains, 70% were isolated from blood cultures.
Antimicrobial agents were obtained from their respective manufacturers: U-76,253 (supplied as the sodium salt of the free acid) from The Upjohn Co., Kalamazoo, Mich.; cephalexin, cefaclor, and erythromycin from Eli Lilly & Co., Indianapolis, Ind.; cefuroxime from Glaxo, Inc., Research Triangle Park, N.C.; amoxicillin and clavulanic acid from Beecham Laboratories, Bristol, Tenn.; trimethoprim and sulfamethoxazole from Hoffmann-La Roche Inc., Nutley, N.J. Laboratory standards were diluted according to the recommendations of the manufacturers and were dispensed into microdilution plates by using a MIC-2000 Plus dispensing machine (Dynatech Laboratories, Inc., Alexandria, Va.) in log2 dilution steps within the range 0.007 to 128 ,ug/ml. For amoxicillin-clavulanate (AMX-CLV), a fixed ratio of 2:1 was tested; MICs were expressed as concentrations of amoxicillin. For trimethoprim-sulfamethoxazole (TMP-SMZ), a fixed ratio of 1:19 was tested, and 0.1 U of thymidine phosphorylase (Burroughs Wellcome Co., Research Triangle Park, N.C.) per ml was added; MICs were expressed as total concentrations of TMP-SMZ. Plates were stored at -70°C until used.
MICs were determined by a standard microdilution method (3) The MICs of the eight antimicrobial agents against the study strains are shown in Table 1 . Activity of U-76,253 was greatest against Streptococcus spp., H. influenzae, and Proteus mirabilis (MICs for .90% of the strains, 0.015 to 0.06 ,ug/ml). Activity against B. catarrhalis, E. coli, Klebsiella spp., and Citrobacter diversus was also consistent (MICs for -90% of the strains, 0.25 to 1 ,ug/ml), although one strain of K. pneumoniae was resistant (MIC, >16 ,ug/ ml). Activity against other members of the family Enterobacteriaceae and Aeromonas hydrophila was more variable (MICs for .90% of the strains, 2 to >16 ,ug/ml), but 132 (72%) of 182 strains were inhibited by .4 ,ug/ml. With occasional strains of Enterobacter spp. and Citrobacter freundii, skipped wells in MIC plates were observed, suggesting that a high mutation rate to resistance exists, as it does for other cephalosporins (2) . Activity against Staphylococcus spp. was consistent but modest (MICs for >90% of the strains, 1 to 8 ,ug/ml). U-76,253 had no activity against Pseudomonas aeruginosa or Enterococcus faecalis (MICs, >16 ,ug/ml).
A previous study from Japan (4) determined the in vitro activity of U-76,253 by using agar dilution. Results were similar to those of this study, although the Japanese study reported greater variability in MICs for staphylococci and found some members of the tribe Proteeae to be relatively more susceptible to U-76,253.
We conclude that U-76,253 is more active than a number of currently available oral antibiotics against most Enterobacteriaceae, although some species are relatively resistant to many of those drugs. U-76,253 will probably also be useful for treating infections caused by H. influenzae, B. catarrhalis, staphylococci, and streptococci but not P. aeruginosa or enterococci. 
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